State of Oklahoma SoonerCare



Xalkori® (Crizotinib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	
Pharmacy billing (NDC:) Start Date (or date of next dose):	
Dose:	Regimen:	
	Billing Provider Informa	tion
Provider NPI:	Provider Name:_	
Provider Phone:	Provider Fax:_	
Prescriber Information		
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
	Criteria	
C. MET amplification? D. Will crizotinib be us Soft Tissue Sarcoma A. Diagnosis of soft tis B. Is disease ALK pos C. Will crizotinib be us Anaplastic Large Cell A. Is disease ALK pos B. Is disease relapsed C. Will crizotinib be us Other, please provide	(first-line or subsequent therapy)? Yes tic lymphoma kinase (ALK) or ROS1 per Yes No Sed as a single-agent only? Yes Nossue sarcoma—Inflammatory Myofibrositive? Yes No Sed as a single-agent only?	No oblastic Tumor (IMT)? Yes No No
Has the member experience	dence of progressive disease while on ed adverse drug reactions related to cr eactions:	izotinib therapy? Yes No
Additional Information:		
Prescriber Signature:	D	ate:
		all information is true and correct to the

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 82 5/23/2023